Project Grant R41AG044960

This Project Grant from the National Science Foundation's Technology, Innovation, and Partnerships program totaling $295,247 will support the development of an innovative medical technology for localized and sustained antibiotic treatment of periprosthetic joint infection. Specifically, the awardee Reselute will design, develop, and validate a proof of concept for an orthopedic spacer implant with a novel porous medium capable of controlled antibiotic elution over 180 days. The implantable...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $840,462.15 to Mississippi State University to investigate methods for preventing biofilm formation by the bacterium Staphylococcus epidermidis on medically relevant surfaces. The key objectives are to: 1) establish the structural and biophysical determinants of how S. epidermidis surface proteins bind to...

This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) provides $535,304 to Rush University Medical Center for research to prevent and treat periprosthetic joint infection (PJI). The key objectives are to: 1) Determine if implants coated with anti-DNABII antibodies can prevent biofilm formation by Staphylococcus aureus on implants in a mouse model...

This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $305,000 aims to develop a novel mammalian cell-based nano-biological coating for implantable medical devices. The key objectives are to: (1) characterize nanoparticles produced by different cells on titanium and stainless-steel orthopedic implants, (2) determine the antibacterial, anti-inflammatory, and bone/fibroblast cell growth properties of the coated surfaces, and (3)...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $208,154 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to evaluate the potential of a novel antimicrobial blue light (ABL) emitting envelope (ABL-ENV) to combat infections related to cardiac implantable electronic devices (CIEDs). The key objectives are to assess the anti-biofilm efficacy of the ABL-ENV...

This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $1,271,407.00 to Georgia Tech Research Corp to engineer antimicrobial hydrogels that can deliver lysostaphin and antibiotics to eliminate bacterial infections and promote bone repair in murine and ovine models. The research aims to establish an injectable hydrogel-based strategy for...

This Project Grant from the National Science Foundation's Engineering program (CFDA 47.041) provides $249,999 to The Trustees of the University of Pennsylvania for the development of a smart dental implant system. The award will support research and educational activities from September 2022 through August 2025. Specifically, the grantee will build a strategy to prevent peri-implant disease through enhancing soft tissue immunity near dental implants. They will develop an ambulatory care platform...

This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Cooperative Agreement award to Reselute, Inc. provides $998,921 to develop a novel implantable orthopedic medical device and procedure to reduce recovery duration and infection risks associated with severe traumatic fractures of the long bones. The project aims to advance a 3D-printed, antibiotic-releasing intramedullary nail to improve upon current standard-of-care implants that are prone to...

This federal Project Grant award of $592,863 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research at the University of Texas Southwestern Medical Center to evaluate a novel biomaterials-based vaccine platform (BIVAX) for preventing Staphylococcus aureus periprosthetic joint infections. The research aims to determine the effects of infection and vaccination on the host immune response and assess the efficacy of...

This Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research Federal Grant Program (CFDA 93.121), provides $663,168 to develop multi-functional 3D printed dental implants to prevent peri-implantitis, a common and challenging implant-related oral infection. The project aims to create silver-doped amorphous magnesium phosphate bioceramic particles and incorporate them into a high-performance polyetheretherketone...